We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-4.85%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.16B
AUM Growth
-$97.2M
Cap. Flow
+$7.64M
Cap. Flow %
0.66%
Top 10 Hldgs %
55.45%
Holding
63
New
12
Increased
17
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$27.1M
2
PEN icon
Penumbra
PEN
+$24.6M
3
ESRX
Express Scripts Holding Company
ESRX
+$24.3M
4
XNCR icon
Xencor
XNCR
+$24M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$20.5M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$39.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$21.6M
4
ELGX
Endologix Inc
ELGX
+$20.8M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$20.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.86%
2 Miscellaneous 1.19%
3 Financials 0.92%
4 Communication Services 0.62%
5 Consumer Staples 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
51
Biogen
BIIB
$32.3B
– –
-677
Closed -$212K
BPMC
52
DELISTED
Blueprint Medicines
BPMC
– –
-27,539
Closed -$818K
DXCM icon
53
DexCom
DXCM
$34.3B
– –
-9,840
Closed -$216K
FBT icon
54
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.9B
– –
-3,090
Closed -$308K
HUM icon
55
Humana
HUM
$46.3B
– –
-1,390
Closed -$246K
IRWD icon
56
Ironwood Pharmaceuticals
IRWD
$682M
– –
-487,704
Closed -$6.49M
SRPT icon
57
Sarepta Therapeutics
SRPT
$2.2B
– –
-640,400
Closed -$39.3M
ITCI
58
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-336,759
Closed -$5.13M
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-505,154
Closed -$23.3M
ALXN
60
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-45,410
Closed -$5.57M
PTLA
61
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-916,927
Closed -$20.8M
AKAO
62
DELISTED
Achaogen Inc
AKAO
– –
-32,300
Closed -$155K
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2016 Portfolio in Review

As of Q4 2016, Redmile Group held 63 positions worth $1.16B, down 7.7% from $1.26B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group's Q4 2016 filing shows 12 new, 17 increased, 17 reduced and 13 closed positions. Its largest new stake was Express Scripts Holding Company: 338,800 shares worth $23.3M. The largest sale was Sarepta Therapeutics, an estimated $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q4 2016 buy was Express Scripts Holding Company: 338,800 shares worth $23.3M.
  • Redmile Group added most to Puma Biotechnology in Q4 2016, an estimated $27.1M increase.
  • Redmile Group's biggest Q4 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $21.6M.
  • Redmile Group fully exited Sarepta Therapeutics in Q4 2016, selling an estimated $39.3M.
  • Redmile Group's ten largest holdings make up 55% of its $1.16B portfolio in Q4 2016.
  • Redmile Group opened 12 new positions and closed 13 in Q4 2016.
  • Redmile Group's portfolio value fell 7.7% quarter-over-quarter to $1.16B.

Based on Redmile Group's 13F filing for Q4 2016, filed 14 Feb 2017.